Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
16
APM Quote, Financials, Valuation and Earnings
Last price:
$1.19
Seasonality move
:
0.15%
Day range:
$1.09 - $1.20
52-week range:
$0.69 - $7.49
Dividend yield:
0%
P/E ratio:
8.94x
P/S ratio:
6.32x
P/B ratio:
0.47x
Volume:
92.5K
Avg. volume:
90.1K
1-year change:
35.28%
Market cap:
$8.5M
Revenue:
--
EPS (TTM):
$0.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$5M | -$0.00 | -100% | -88.64% | $7.20 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $7.99 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APM
Aptorum Group Ltd.
|
$1.19 | -- | $8.5M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.68 | $9.52 | $447.1M | -- | $0.00 | 0% | 8.72x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.87 | $17.94 | $2.4M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$2.30 | $7.20 | $365.7M | -- | $0.00 | 0% | 718.19x |
|
NCNA
NuCana Plc
|
$3.34 | $104.00 | $13.9M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.53 | $7.99 | $181.8M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APM
Aptorum Group Ltd.
|
-- | -9.132 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | 0.602 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Aptorum Group Ltd. vs. Competitors
-
Which has Higher Returns APM or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Aptorum Group Ltd.'s net margin of -373.3%. Aptorum Group Ltd.'s return on equity of -- beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital APMAptorum Group Ltd.-- -- -- AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About APM or AUTL?
Aptorum Group Ltd. has a consensus price target of --, signalling upside risk potential of 13292.86%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 480.62%. Given that Aptorum Group Ltd. has higher upside potential than Autolus Therapeutics Plc, analysts believe Aptorum Group Ltd. is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings APMAptorum Group Ltd.0 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is APM or AUTL More Risky?
Aptorum Group Ltd. has a beta of -0.206, which suggesting that the stock is 120.612% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock APM or AUTL?
Aptorum Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptorum Group Ltd. pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APM or AUTL?
Aptorum Group Ltd. quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Aptorum Group Ltd.'s net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Aptorum Group Ltd.'s price-to-earnings ratio is 8.94x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptorum Group Ltd. is 6.32x versus 8.72x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APMAptorum Group Ltd.6.32x 8.94x -- -- AUTLAutolus Therapeutics Plc8.72x -- $21.1M -$78.6M
-
Which has Higher Returns APM or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Aptorum Group Ltd.'s net margin of --. Aptorum Group Ltd.'s return on equity of -- beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital APMAptorum Group Ltd.-- -- -- BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About APM or BDRX?
Aptorum Group Ltd. has a consensus price target of --, signalling upside risk potential of 13292.86%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 5406.23%. Given that Aptorum Group Ltd. has higher upside potential than Biodexa Pharmaceuticals Plc, analysts believe Aptorum Group Ltd. is more attractive than Biodexa Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings APMAptorum Group Ltd.0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is APM or BDRX More Risky?
Aptorum Group Ltd. has a beta of -0.206, which suggesting that the stock is 120.612% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock APM or BDRX?
Aptorum Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptorum Group Ltd. pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APM or BDRX?
Aptorum Group Ltd. quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Aptorum Group Ltd.'s net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Aptorum Group Ltd.'s price-to-earnings ratio is 8.94x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptorum Group Ltd. is 6.32x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APMAptorum Group Ltd.6.32x 8.94x -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns APM or MREO?
Mereo BioPharma Group Plc has a net margin of -- compared to Aptorum Group Ltd.'s net margin of -2923.31%. Aptorum Group Ltd.'s return on equity of -- beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital APMAptorum Group Ltd.-- -- -- MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About APM or MREO?
Aptorum Group Ltd. has a consensus price target of --, signalling upside risk potential of 13292.86%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $7.20 which suggests that it could grow by 213.11%. Given that Aptorum Group Ltd. has higher upside potential than Mereo BioPharma Group Plc, analysts believe Aptorum Group Ltd. is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings APMAptorum Group Ltd.0 0 0 MREOMereo BioPharma Group Plc6 0 0 -
Is APM or MREO More Risky?
Aptorum Group Ltd. has a beta of -0.206, which suggesting that the stock is 120.612% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.425%.
-
Which is a Better Dividend Stock APM or MREO?
Aptorum Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptorum Group Ltd. pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APM or MREO?
Aptorum Group Ltd. quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. Aptorum Group Ltd.'s net income of -- is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Aptorum Group Ltd.'s price-to-earnings ratio is 8.94x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptorum Group Ltd. is 6.32x versus 718.19x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APMAptorum Group Ltd.6.32x 8.94x -- -- MREOMereo BioPharma Group Plc718.19x -- -- -$7M
-
Which has Higher Returns APM or NCNA?
NuCana Plc has a net margin of -- compared to Aptorum Group Ltd.'s net margin of --. Aptorum Group Ltd.'s return on equity of -- beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital APMAptorum Group Ltd.-- -- -- NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About APM or NCNA?
Aptorum Group Ltd. has a consensus price target of --, signalling upside risk potential of 13292.86%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 622654.49%. Given that NuCana Plc has higher upside potential than Aptorum Group Ltd., analysts believe NuCana Plc is more attractive than Aptorum Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings APMAptorum Group Ltd.0 0 0 NCNANuCana Plc0 1 0 -
Is APM or NCNA More Risky?
Aptorum Group Ltd. has a beta of -0.206, which suggesting that the stock is 120.612% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock APM or NCNA?
Aptorum Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptorum Group Ltd. pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APM or NCNA?
Aptorum Group Ltd. quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Aptorum Group Ltd.'s net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Aptorum Group Ltd.'s price-to-earnings ratio is 8.94x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptorum Group Ltd. is 6.32x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APMAptorum Group Ltd.6.32x 8.94x -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns APM or TLSA?
Tiziana Life Sciences Ltd. has a net margin of -- compared to Aptorum Group Ltd.'s net margin of --. Aptorum Group Ltd.'s return on equity of -- beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APMAptorum Group Ltd.-- -- -- TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About APM or TLSA?
Aptorum Group Ltd. has a consensus price target of --, signalling upside risk potential of 13292.86%. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 422.11%. Given that Aptorum Group Ltd. has higher upside potential than Tiziana Life Sciences Ltd., analysts believe Aptorum Group Ltd. is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings APMAptorum Group Ltd.0 0 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is APM or TLSA More Risky?
Aptorum Group Ltd. has a beta of -0.206, which suggesting that the stock is 120.612% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.
-
Which is a Better Dividend Stock APM or TLSA?
Aptorum Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptorum Group Ltd. pays -- of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APM or TLSA?
Aptorum Group Ltd. quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Aptorum Group Ltd.'s net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Aptorum Group Ltd.'s price-to-earnings ratio is 8.94x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptorum Group Ltd. is 6.32x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APMAptorum Group Ltd.6.32x 8.94x -- -- TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
